Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone dose comparison in adolescents with schizophrenia
NCT00034749Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in total Positive and Negative Syndrome Scale from baseline at 8 weeks. Started Apr 2001; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00034749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034749.